FindTrial
Sign In

Inflence of Target-controlled infusion of remifentanil on incidence of adverse reactions introduced by hemabate during cesarean section

Inflence of Target-controlled infusion of remifentanil on incidence of adverse reactions introduced by hemabate during cesarean section

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016292
Enrollment
Unknown
Registered
2018-05-24
Start date
2018-05-23
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section

Interventions

1:saline TCI
2:0.5ng/ml remifentanil TCI
3:1.0ng/ml remifentanil TCI
4:1.5ng/ml remifentanil TCI
5:2.0ng/ml remifentanil TCI

Sponsors

Jiaxing Maternity and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
19 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective cesarean section by using combined spinal-epidural anaesthesia

Exclusion criteria

Exclusion criteria: Significant medical or obstetric morbidity, history of allergy to bupivacaine, contraindication for spinal aneshtesia, spinal puncture failure, inconformity of spinal spread in both sides.

Design outcomes

Primary

MeasureTime frame
complication rate;BIS;RR;SPO2;BP;remifentanil dose;—

Countries

China

Contacts

Public ContactChangna Wei

Jiaxing Maternity and Child Health Care Hospital

544631360@qq.com+86 18267382732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026